Efficacy and Safety of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial

RCT (n=391) reported that this oral, once-daily Janus kinase 1 selective inhibitor was well tolerated and significantly improved signs and symptoms of atopic dermatitis based on IGA response and EASI-75 compared with placebo in adolescent and adult patients at week 12.

SPS commentary:

Patients in the 200-and 100-mg abrocitinib groups vs the placebo group achieving Investigator Global Assessment (IGA) response (i.e. clear [0] or almost clear [1], with improvement of ≥2 grades) was 59 of 155 [38.1%] and 44 of 155 [28.4%] vs 7 of 77 [9.1%]; p< 0.001; and proportion of patients achieving at least 75% improvement in Eczema Area and Severity Index score (EASI-75) was 94 of 154 [61.0%] and 69 of 155 [44.5%] vs 8 of 77 [10.4%]; p <0 .001.


JAMA Dermatology